GLG News by Oncologists who Treat Hematologic Malignancies (US)

This immunotherapeutic agent in association with interleukin 2 or interferon may be effective in renal cell carcinoma (RCC). To be tested in a phase III trial (against what??)

That appears to be a well contructed phase III trial adds ASA404 or a placebo to Taxol/Carboplatin. Nothing exotic, endpoints are overall survival (OS) as well as OS in Squams and non Squams.

Genetic profiling will tell us who should or should not receive particular anti neoplastic agents. This is "personalized" therapy that has been predicted x years.

China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...

Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await

Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival

For the first time in decades, several drugs like Temodar and Avastin and tumor vaccines ( Avant and others) have shown increased overall survival even in adavnaced and recurrent brain tumors as glioblastoma multiforme. Several agents are in the pipeline, and more Big Pharma involvement is expected...

The epidermal growth factor antagonist Erbitux did not improve response rates in newly diagnosed patients with advanced non-small cell lung cancer ( NSCLC).  Many patients had hypersensitivity reactions to Cetuximab, which has to be content with its role in colon cancer treatment and to some extent...

In a clinical trial from MD Anderson, Celgene's oral immunomodulatory agent , Revlimid showed a modest, yet impressive, overall response rate of 32% in patients with refractory, heavily pre-treated CLL. With already proven efficacy in other hematological malignancies, like multiple myeloma, myelofibrosis,...

Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.